Clinical Trials Browser

poly(I).poly(c12,U) × Dermatologic × 90 days × Clear all

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

Melanoma